- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Expanding Use of Biosimilar Pegfilgrastim Could Save Millions, Study Says
Expanding access to biosimilar pegfilgrastim (Ziextenzo) for patients at intermediate risk of febrile neutropenia and converting patients at high risk who are on the reference product (Neulasta) could save millions in healthcare costs, according to new study results.
A new study funded by Sandoz indicated that expanding access to biosimilar pegfilgrastim (Ziextenzo) to patients at intermediate risk of developing febrile neutropenia (FN) and converting patients at high risk who are already taking the reference product (Neulasta) could save millions of dollars in health care costs.
Reference pegfilgrastim tends to be prescribed only for patients with cancer who are at a high risk of FN, rather than for those who are at intermediate and low risk, due to its high cost.
A poster on the study was presented during the Academy of Managed Care Pharmacy’s AMCP eLearning Days virtual meeting in April.
“Expanding biosimilar pegfilgrastim prophylaxis to patients at intermediate risk of FN would not only reduce total costs but also reduce healthcare resource utilization, including hospitalization and emergency department visits,” said Weijia Wang, MSc, an associate director at Sandoz and the study’s lead author.
The investigators created a 5-year projection of savings from converting patients from reference to biosimilar pegfilgrastim and applied it to a hypothetical 1-million member health plan with a mixture of commercial payer and Medicare plan participants. Converting patients at high risk of FN to the biosimilar would have resulted in savings of $5.3 million in 2020, rising to $32.8 million by 2024, researchers said.
To read more of this story, visit The Center for Biosimilars.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
